Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000628523 | SCV000749425 | likely benign | Gorlin syndrome; Medulloblastoma | 2024-01-28 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV001011627 | SCV001171971 | likely benign | Hereditary cancer-predisposing syndrome | 2019-11-08 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Ce |
RCV003424198 | SCV004127290 | likely benign | not provided | 2024-06-01 | criteria provided, single submitter | clinical testing | SUFU: BP4, BP7 |
Prevention |
RCV004547773 | SCV004785765 | likely benign | SUFU-related disorder | 2021-10-15 | no assertion criteria provided | clinical testing | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). |